Explore how KIFFIK is transforming diagnostics with a scalable ISF platform and strong market opportunity.
Why invest in KIFFIK?
550B+ Addressable Market
Diagnostics is one of the fastest growing sectors with high demand for convenient, non-invasive testing.
First-Mover Advantage
No one else is delivering aptamer-based, ISF-driven diagnostics at scale.
Platform Scalability
Oncology is just the beginning — our technology addresses cardiometabolic, infectious, and wellness markets.
The KIFFIK Platform Opportunity
KIFFIK’s platform is positioned to capture a meaningful share of the rapidly expanding diagnostics market and beyond, with a total addressable market (TAM) projected to reach approximately $1.8 trillion by 2035. With nearly $550 billion accessible today and annual growth rates of 8–10%, KIFFIK is uniquely placed to drive innovation across healthcare verticals including oncology, cardiometabolic, infectious disease, and neurological applications.
TAM 2035: ≈ $
0
Trillion
Accessible Today: ≈ $
0
Billion
Annual Growth Rate: 8-
0
% CAGR
|
Vertical
|
2025 TAM
|
CAGR
|
2035 TAM
|
KIFFIK Role
|
|---|---|---|---|---|
|
Oncology Diagnosis & Monitoring
|
$150B
|
8.2%
|
$325B
|
Tumor ISF biomarkers, MRD tracking
|
|
Cardiovascular Diagnostics
|
$85B
|
7.5%
|
$175B
|
ISF troponins, BMP
|
|
Autoimmune Monitoring
|
$60B
|
7.1%
|
$120B
|
Cytokine storm detection
|
|
Infectious Disease
|
$35B
|
5.8%
|
$62B
|
ISF viral load tracking
|
|
Neurological
|
$45B
|
8.5%
|
$105B
|
Alzheimer's, concussion monitoring
|
|
Metabolic Disorders
|
$100B
|
9.1%
|
$235B
|
ISF lipids, insulin, ApoB
|
|
Clinical Trials (Drug Development)
|
$70B
|
7.9%
|
$150B
|
Biomarker endpoints, real-time feedback
|
|
Companion Diagnostics
|
$80B
|
9.3%
|
$195B
|
Drug-diagnostic pairs
|
|
Remote/Home Health
|
$120B
|
10.5%
|
$310B
|
ISF Wearables
|
|
Veterinary Diagnostics
|
$25B
|
6.2%
|
$45B
|
Pet/livestock ISF monitoring
|
|
Military & Defense
|
$15B
|
5.0%
|
$24B
|
ISF for TBI, chemical exposure
|
|
Consumer Wellness
|
$85B
|
11.2%
|
$250B
|
Personalized health, anti-aging
|
Embedded Sources
Led by experts, built for scale
Our leadership team brings deep experience in diagnostics, commercial growth, and medtech innovation — supported by a world-class advisory board.
"We are thrilled to announce our partnership with Duracell, a company that shares our commitment to innovation and excellence. Integrating Duracell's trusted battery technology into our biomonitoring devices represents a significant leap forward in our mission to advance health monitoring solutions. This collaboration underscores our dedication to delivering superior, dependable products that improve the quality of life for individuals worldwide."
George Cagna
CEO, KIFFIK Biomedical
Access our investor materials.
Download our one-pager to learn more about the KIFFIK opportunity.
Let's start a conversation
We’re actively engaging strategic investors, M&A partners, and early collaborators.
